UCB PHARMA SA
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Public, Subsidiary
- Established
- 1928-01-01
- Employees
- 9K
- Market Cap
- $34.9B
A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-11-11
- Last Posted Date
- 2017-10-30
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 13
- Registration Number
- NCT02602860
- Locations
- 🇺🇸
Ep0074 001, New Haven, Connecticut, United States
A Study of Certolizumab Pegol to Evaluate Pharmacokinetics and Safety in Adult Healthy Chinese Subjects
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2015-08-14
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 36
- Registration Number
- NCT02365948
- Locations
- 🇨🇳
1, Shanghai, China
An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044
- First Posted Date
- 2014-12-18
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 347
- Registration Number
- NCT02319642
- Locations
- 🇨🇳
013, Beijing, China
🇨🇳025, Beijing, China
🇨🇳021, Beijing, China
Study to Assess Safety, Tolerability, Pharmacokinetic & Pharmacodynamic Effect of UCB5857 in Healthy & Psoriatic Subject
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-12-01
- Last Posted Date
- 2014-12-01
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 57
- Registration Number
- NCT02303509
- Locations
- 🇬🇧
001, Harrow, United Kingdom
Single-site, Open-label, Randomized, Cross-over Study in Healthy Chinese Subjects to Evaluate the Bioequivalence of Single-dose Rotigotine Transdermal Patch Comparing 2 Different Formulations
- First Posted Date
- 2014-02-25
- Last Posted Date
- 2014-07-29
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 50
- Registration Number
- NCT02070796
- Locations
- 🇨🇳
1, Hong Kong, China
Bioavailability/Bioequivalence Study Between Lacosamide Tablet and Solution for Infusion in Healthy Japanese Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-11-18
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 26
- Registration Number
- NCT01986608
- Locations
- 🇬🇧
001, Harrow, Middlesex, United Kingdom
A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures.
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2019-05-07
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 55
- Registration Number
- NCT01969851
- Locations
- 🇺🇸
112, Hackensack, New Jersey, United States
🇺🇸101, Orlando, Florida, United States
🇫🇷309, Ile-De-France, France
Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine in Healthy Korean Subjects
- First Posted Date
- 2013-10-17
- Last Posted Date
- 2014-10-20
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 48
- Registration Number
- NCT01964573
Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2017-08-15
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 436
- Registration Number
- NCT01954121
- Locations
- 🇨🇳
16, Changchun City, China
🇨🇳1, Guangzhou, China
🇨🇳20, Guangzhou, China
Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures
- First Posted Date
- 2013-08-13
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 404
- Registration Number
- NCT01921205
- Locations
- 🇨🇴
172, Floridablanca, Colombia
🇵🇱430, Warszawa, Poland
🇵🇱420, Kielce, Poland
© Copyright 2024. All Rights Reserved by MedPath